Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mike M who wrote (799)	8/25/1999 11:04:00 PM
From: DanZ	Read Replies (1) \| Respond to of 5582

Mike, <I got the feeling from Gary that he wasn't necessarily expecting review from the first study.> Either Gary gave you the wrong impression or he was being overly conservative again. You might want to call Gary and ask him directly; however, I would suggest that you talk to Brown about Zicam instead. He's more involved with it day to day than Gary. Brown gave me the impression that they are cautiously optimistic that the first study will be accepted by the NEJM. He also told me that there's no link whatsoever between the review of the first study and the other studies. He said that they might not even submit the second study to the NEJM. They might submit it to a different publication such as JAMA. GumTech is conducting the second clinical study because they want to make claims with regard to efficacy on the packaging and in their advertising. According to their legal council, who specializes in FDA and FTC issues, they need to conduct the second study before they can make these claims. The study for prevention is as you said, another application for Zicam.